Comparison of 2-year-results of mitomycin C-augmented trabeculectomy with or without cataract extraction in glaucoma patients

Published:October 19, 2018DOI:



      Comparison of the 2-year results of phacotrabeculectomy (CET) and trabeculectomy (TE), both augmented with mitomycin C.


      This prospective study enclosed 246 eyes in 246 consecutive patients that had undergone trabeculectomy (n = 85) or phacotrabeculectomy (n = 161, hereof n = 10 phacoretrabeculectomy) augmented by mitomycin C. Endpoints were best corrected visual acuity (BCVA), intraocular pressure (IOP), and number of antiglaucomatous medications at baseline, 3 months, and 2 years postoperatively. Postoperative management involved local steroid application and laser suture lysis according to a standardized protocol.


      Both interventions reduced IOP statistically significant and stable. In the phacotrabeculectomy group BCVA improved from 0.45 ± 0.47 logMAR units preoperatively to 0.28 ± 0.54 logMAR units at 2 years (p < 0.001) and remained unchanged in the trabeculectomy group. After 2 years IOP reduced from 22.5 ± 7.2 mm Hg preoperatively to 11.5 ± 3.1 mm Hg in the TE group and from 20.0 ± 5.4 mm Hg to 12.5 ± 4.8 mm Hg in the CET group (both p > 0.05). The mean number of antiglaucomatous medications was significantly reduced from 2 ± 1 in both groups to 0.3 in the trabeculectomy group and to 0.4 in the phacotrabeculectomy group. With this standardized surgical procedure and postoperative protocol, there was no need for local postoperative antimetabolites. No Tenon's capsule cysts developed. In the subgroup of patients with phacoretrabeculectomy BCVA and IOP improvements were comparable to the phacotrabeculectomy group outcomes.


      Phacotrabeculectomy is comparably as effective as trabeculectomy alone in reducing IOP and the need for antiglaucomatous medication over a time interval of 2 years. We found indications that this favourable therapeutic effect is also true for patients needing phacoretrabeculectomy treatment.



      Comparer les résultats à 2 ans de la phacotrabéculectomie et de la trabéculectomie, avec adjonction de mitomycine C dans les 2 cas.


      Cette étude prospective regroupait 246 yeux de 246 patients consécutifs qui avaient subi une trabéculectomie (n = 85) ou une phacotrabéculectomie (n = 161, dont 10 cas de phaco-retrabéculectomie) avec adjonction de mitomycine C. Les paramètres de mesure étaient les suivants : meilleure acuité visuelle corrigée (MAVC), pression intraoculaire (PIO) et nombre d'antiglaucomateux au départ ainsi que 3 mois et 2 ans après l'intervention. La prise en charge postopératoire comprenait l'application locale de stéroïde et la lyse de suture au laser, conformément à un protocole standardisé.


      Les deux types d'interventions ont permis une baisse stable et statistiquement significative de la PIO. Dans le groupe phacotrabéculectomie, la MAVC est passée de 0,45 ± 0,47 logMAR avant l'intervention à 0,28 ± 0,54 logMAR après 2 ans (p < 0,001) et est demeurée la même dans le groupe trabéculectomie. La PIO est passée de 22,5 ± 7,2 mm Hg avant l'intervention à 11,5 ± 3,1 mm Hg après 2 ans dans le groupe trabéculectomie et de 20,0 ± 5,4 mm Hg à 12,5 ± 4,8 mm Hg dans le groupe phacotrabéculectomie (p > 0,05 dans les 2 cas). Le nombre moyen d'antiglaucomateux a diminué significativement, passant de 2 ± 1 dans les 2 groupes à 0,3 dans le groupe trabéculectomie et à 0,4 dans le groupe phacotrabéculectomie. Grâce à cette procédure chirurgicale standardisée et au protocole postopératoire, aucun patient n'a eu besoin d'antimétabolites locaux en période postopératoire. De plus, il ne s'est produit aucun kyste de la capsule de Tenon. Dans le sous-groupe de patients ayant subi une phaco-retrabéculectomie, les améliorations de la MAVC et de la PIO étaient comparables aux résultats obtenus dans le groupe phacotrabéculectomie.


      La phacotrabéculectomie offre une efficacité comparable à celle de la trabéculectomie seule pour ce qui est de la réduction de la PIO et de l'administration d'antiglaucomateux sur une période de 2 ans. Selon nos observations, il en est de même pour les patients qui doivent subir une phaco-retrabéculectomie.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Friedman DS
        • Jampel HD
        • Lubomski LH
        • et al.
        Surgical strategies for coexisting glaucoma and cataract: an evidence-based update.
        Ophthalmology. 2002; 109: 1902−13
        • AGIS Investigators
        The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy.
        Arch Ophthalmol. 2001; 119: 1771−9
        • Husain R
        • Aung T
        • Gazzard G
        • et al.
        Effect of trabeculectomy on lens opacities in an East Asian population.
        Arch Ophthalmol. 2006; 124: 787−92
        • Hylton C
        • Congdon N
        • Friedman D
        • et al.
        Cataract after glaucoma filtration surgery.
        Am J Ophthalmol. 2003; 135: 231−2
        • Husain R
        • Liang S
        • Foster PJ
        • et al.
        Cataract surgery after trabeculectomy: the effect on trabeculectomy function.
        Arch Ophthalmol. 2012; 130: 165−70
        • Siriwardena D
        • Kotecha A
        • Minassian D
        • Dart JK
        • Khaw PT
        Anterior chamber flare after trabeculectomy and after phacoemulsification.
        Br J Ophthalmol. 2000; 84: 1056−7
        • Chen DZ
        • Koh V
        • Sng C
        • Aquino MC
        • Chew P
        Complications and outcomes of primary phacotrabeculectomy with mitomycin C in a multi-ethnic asian population.
        PloS One. 2015; 10e0118852
        • European Glaucoma Society
        Terminology and guidelines for glaucoma.
        (Available at:) (Accessed June 8, 2014)
        • Chang L
        • Thiagarajan M
        • Moseley M
        • et al.
        Intraocular pressure outcome in primary 5FU phacotrabeculectomies compared with 5FU trabeculectomies.
        J Glaucoma. 2006; 15: 475−81
        • Kleinmann G
        • Katz H
        • Pollack A
        • Schechtman E
        • Rachmiel R
        • Zalish M
        Comparison of trabeculectomy with mitomycin C with or without phacoemulsification and lens implantation.
        Ophthalmic Surg Lasers. 2002; 33: 102−8
        • Ogata-Iwao M
        • Inatani M
        • Takihara Y
        • Inoue T
        • Iwao K
        • Tanihara H
        A prospective comparison between trabeculectomy with mitomycin C and phacotrabeculectomy with mitomycin C.
        Acta Ophthalmol. 2013; 91: e500−1
        • Tham CC
        • Kwong YY
        • Leung DY
        • et al.
        Phacoemulsification vs phacotrabeculectomy in chronic angle-closure glaucoma with cataract: complications [corrected].
        Arch Ophthalmol. 2010; 128: 303−11
        • Lochhead J
        • Casson RJ
        • Salmon JF
        Long term effect on intraocular pressure of phacotrabeculectomy compared to trabeculectomy.
        Br J Ophthalmol. 2003; 87: 850−2
        • Singh RP
        • Goldberg I
        • Mohsin M
        The efficacy and safety of intraoperative and/or postoperative 5-fluorouracil in trabeculectomy and phacotrabeculectomy.
        Clin Experiment Ophthalmol. 2001; 29: 296−302
        • Donoso R
        • Rodriguez A
        Combined versus sequential phacotrabeculectomy with intraoperative 5-fluorouracil.
        J Cataract Refract Surg. 2000; 26: 71−4
        • Murthy SK
        • Damji KF
        • Pan Y
        • Hodge WG
        Trabeculectomy and phacotrabeculectomy, with mitomycin-C, show similar two-year target IOP outcomes.
        Canadian J Ophthalmol. 2006; 41: 51−9
        • Buys YM
        • Chipman ML
        • Zack B
        • Rootman DS
        • Slomovic AR
        • Trope GE
        Prospective randomized comparison of one- versus two-site Phacotrabeculectomy two-year results.
        Ophthalmology. 2008; 115: 1130−3
        • Jin GJ
        • Crandall AS
        • Jones JJ
        Phacotrabeculectomy: assessment of outcomes and surgical improvements.
        J Cataract Refract Surg. 2007; 33: 1201−8
        • Rao HL
        • Maheshwari R
        • Senthil S
        • Prasad KK
        • Garudadri CS
        Phacotrabeculectomy without mitomycin C in primary angle-closure and open-angle glaucoma.
        J Glaucoma. 2011; 20: 57−62
        • Derick RJ
        • Evans J
        • Baker ND
        Combined phacoemulsification and trabeculectomy versus trabeculectomy alone: a comparison study using mitomycin-C.
        Ophthalmic Surg Lasers. 1998; 29: 707−13
        • Francis BA
        • Winarko J
        Combined trabectome and cataract surgery versus combined trabeculectomy and cataract surgery in open-angle glaucoma.
        Clin Surg Ophthalmol. 2001; 29: 4−10
        • Meyer LM
        • Graf NE
        • Philipp S
        • et al.
        Two-year outcome of repeat trabeculectomy with mitomycin C in primary open-angle and PEX glaucoma.
        Eur J Ophthalmol. 2015; 25: 185−91
        • Shaarawy TM
        • Sherwood MB
        • Grehn F
        Guidelines on design and reporting of glaucoma surgical trials.
        Kugler Publications, World Glaucoma Association. Amsterdam, The Netherlands2009
        • Husain R
        The management of patients with cataracts and medically uncontrolled glaucoma.
        Medical Hypothesis Discov Innov Ophthalmol. 2014; 3: 20−30
        • Naveh N
        • Kottass R
        • Glovinsky J
        • Blumenthal M
        • Bar-Sever D
        The long-term effect on intraocular pressure of a procedure combining trabeculectomy and cataract surgery, as compared with trabeculectomy alone.
        Ophthalmic Surg. 1990; 21: 339−45
        • Shields MB
        Another reevaluation of combined cataract and glaucoma surgery.
        Am J Ophthalmol. 1993; 115: 806−11
        • Belyea DA
        • Dan JA
        • Lieberman MF
        • Stamper RL
        Midterm follow-up results of combined phacoemulsification, lens implantation, and mitomycin-C trabeculectomy procedure.
        J Glaucoma. 1997; 6: 90−8
        • Shin DH
        • Iskander NG
        • Ahee JA
        • et al.
        Long-term filtration and visual field outcomes after primary glaucoma triple procedure with and without mitomycin-C.
        Ophthalmology. 2002; 109: 1607−11
        • Shingleton BJ
        • Wooler KB
        • Bourne CI
        • O'Donoghue MW
        Combined cataract and trabeculectomy surgery in eyes with pseudoexfoliation glaucoma.
        J Cataract Refractive Surg. 2011; 37: 1961−70
        • Investigators AGIS
        The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.
        Am J Ophthalmol. 2000; 130: 429−40